To the best of our knowledge, there are no available data in the literature ascribing the expression pattern of the SKP2 gene to the treatment response, and the available information is suggestive of the role of SKP2 in the pathogenesis of CML, although it remains to be elucidated. The gene discussed is SKP2; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.